10 BLOOMFIELD AVE PINE BROOK, NJ 07058 Get Directions
10 BLOOMFIELD AVE PINE BROOK, NJ 07058 Get Directions
Alvogen is the next generation pharmaceuticals company. Our business model ensures competitive advantage through focused in-house capabilities and a network of partners for enhanced speed and flexibility. Alvogen currently has commercial operations in 34 countries around the globe, with regional hubs based in North America, Romania and Taiwan.
Our passionate team is committed to continue to grow our business around the world and to becoming a top 10 global generic pharmaceuticals player. North America is our largest market with over 60 pending ANDA filings. Other markets include Romania, Hungary, Korea, Taiwan, Bulgaria and China.
Alvogen is already well advanced in the field of biopharmaceuticals and currently markets several biosimilars in selected regions through strategic alliances. Over $500 million are being invested in the development of monoclonal antibodies and state-of-the art manufacturing capabilities.
Alvogen has commercial operations in more than 30 countries, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania. Alvogen's lines of business include: product development, contract manufacturing and research (CMO), and sales of generic medicines (Gx and Hx), biosimilars and OTC's.
Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology in addition to a fast growing portfolio of biosimilars and OTC products.
© Dun & Bradstreet, Inc. 2025. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.